Alberto Pavan

Venice, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.

Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.

Journal: Cancer

Published: December 16, 2025

Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World Study.

Chemoimmunotherapy Combinations in Elderly Patients with Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression < 50%: Results from an Italian Real-World Study.

Journal: Journal of clinical medicine

Published: November 23, 2025

Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational study.

Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational study.

Journal: Frontiers in oncology

Published: October 13, 2025

Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry.

Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry.

Journal: The oncologist

Published: September 19, 2025

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database.

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 16, 2025

Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas database.

Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas database.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 02, 2025

Endoscopic ultrasound with bronchoscope fine-needle biopsy in the diagnosis of suspected malignant pulmonary lesions with crown-cut needle: a retrospective study.

Endoscopic ultrasound with bronchoscope fine-needle biopsy in the diagnosis of suspected malignant pulmonary lesions with crown-cut needle: a retrospective study.

Journal: Minerva medica

Published: May 15, 2025

Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study.

Real-world effectiveness and safety of first-line chemoimmunotherapy combinations in metastatic non-small cell lung cancer with programmed death ligand-1 < 50%: results from an Italian observational study.

Journal: Cancer immunology, immunotherapy : CII

Published: March 09, 2025

Real-Life Comparison of Diagnostic Yield and Sample Adequacy of 22 G and 25 G EBUS-TBNB Needles: A Retrospective Study.

Real-Life Comparison of Diagnostic Yield and Sample Adequacy of 22 G and 25 G EBUS-TBNB Needles: A Retrospective Study.

Journal: Journal of clinical medicine

Published: January 25, 2025

Extensive-stage small-cell lung cancer in patients receiving atezolizumab plus carboplatin-etoposide: stratification of outcome based on a composite score that combines gene expression profiling and immune characterization of microenvironment.

Extensive-stage small-cell lung cancer in patients receiving atezolizumab plus carboplatin-etoposide: stratification of outcome based on a composite score that combines gene expression profiling and immune characterization of microenvironment.

Journal: Journal for immunotherapy of cancer

Published: June 13, 2024

Immune-related adverse events in patients treated with immunotherapy for locally advanced or metastatic NSCLC in real-world settings: a systematic review and meta-analysis.

Immune-related adverse events in patients treated with immunotherapy for locally advanced or metastatic NSCLC in real-world settings: a systematic review and meta-analysis.

Journal: Frontiers in oncology

Published: April 10, 2024

Editorial: Updates on combination therapy for lung cancer volume II.

Editorial: Updates on combination therapy for lung cancer volume II.

Journal: Frontiers in oncology

Published: February 28, 2024

Showing 1-12 of 40

Last Updated: 09/26/2026